Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

IASO Acquires Innovent’s Share of BCMA CAR-T in Exchange for 18% of IASO

publication date: Jul 5, 2024

IASO Bio announced a plan to acquire Innovent’s share of the rights to their jointly developed BCMA CAR-T therapy in exchange for an 18% share of IASO. One year ago, China approved Fucaso® (Equecabtagene Autoleucel) as a fourth-line therapy for relapsed/refractory multiple myeloma (RRMM) patients. IASO will have all global commercial rights to Fucaso®, including intellectual property rights, and will responsible for developing, manufacturing and commercializing the CAR-T, while Innovent will become a strategic shareholder of IASO Bio. Innovent said the agreement will lead to other cooperative projects between the companies. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here